WARRINGTON, Pa., Nov. 10, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that Thomas F. Miller, Ph.D., Senior Vice President of Corporate Development of Discovery Labs, will present an update on the Company's recent progress at the Lazard Capital Markets 6th Annual Healthcare Conference to be held in New York. The conference will be simultaneously webcast over the Internet.
Dr. Miller is scheduled to present at 1:10 PM EST on Tuesday, November 17, 2009. The presentation will be available through a live audio webcast at http://www.wsw.com/webcast/lz6/dsco/ or Discovery Labs' web site, www.discoverylabs.com. A replay of the audio webcast will be available on both websites for thirty days.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 Surfactant Technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary Capillary Aerosolization Technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.